Strongbridge Biopharma acquires US rights to Keveyis (dichlorphenamide) from Taro Pharma to treat primary periodic paralysis.

Strongbridge Biopharma plc,, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced that the Company has acquired the U.S. rights to Keveyis (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. Keveyis was approved by the FDA in August 2015 to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis, which is a group of rare hereditary disorders that causes potentially severe episodes of muscle weakness and/or paralysis.

Strongbridge expects to commercially launch Keveyis in the U.S. in April 2017. Taro has agreed to continue to manufacture Keveyis for Strongbridge under an exclusive supply agreement at least for the period of Keveyis orphan exclusivity, subject to certain commercial terms and conditions, including minimum supply purchases. Since May 2016, Taro has been supplying Keveyis to patients through a compassionate use program. Strongbridge will continue this program through at least April 1, 2017. Strongbridge is committed to working with existing U.S. Keveyis patients to ensure continuity of treatment.